Abivax (ABVX) Return on Assets (2025 - 2026)
Abivax's (ABVX) quarterly Return on Assets came in at 0.01% in Q1 2026, little changed year-on-year from 0.01% in Q1 2025, and down 9.69% quarter-over-quarter from 0.01% in Q4 2025.
Abivax (ABVX) Return on Assets (2025 - 2026) Analysis & Trends
Abivax's Return on Assets history runs 2 years deep, the most recent figure standing at 0.01% for Q1 2026.
- On a quarterly basis, Return on Assets changed 0.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 0.0% change from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
- Return on Assets retreated to 0.01% in Q1 2026 per ABVX's latest filing, from 0.01% in the prior quarter.
- Across five years, Return on Assets topped out at 0.01% in Q4 2025 and bottomed at 0.01% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -0.69% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -0.01% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.80% |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 0.00% |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |